Omeros (NASDAQ:OMER) Upgraded at Zacks Investment Research
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
A number of other analysts have also recently issued reports on the company. Wedbush set a $20.00 price objective on Plymouth Industrial Reit and gave the company a buy rating in a research report on Monday, May 20th. ValuEngine cut Yirendai from a sell rating to a strong sell rating in a report on Wednesday, June 26th. HC Wainwright set a $55.00 price target on Acer Therapeutics and gave the stock a buy rating in a report on Tuesday, May 28th. Cantor Fitzgerald reissued a buy rating and set a $71.00 price target on shares of ExlService in a report on Monday, May 6th. Finally, BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $26.50.
Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The firm had revenue of $21.80 million during the quarter, compared to the consensus estimate of $23.18 million. During the same period last year, the firm posted ($0.62) earnings per share. The firm’s revenue was up 1271.1% on a year-over-year basis. Equities analysts forecast that Omeros will post -1.51 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. DAVENPORT & Co LLC lifted its position in shares of Omeros by 12.6% during the second quarter. DAVENPORT & Co LLC now owns 71,250 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 8,000 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Omeros during the first quarter worth $69,000. DekaBank Deutsche Girozentrale lifted its position in shares of Omeros by 21.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 18,700 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 3,300 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Omeros by 19.4% during the first quarter. Rhumbline Advisers now owns 86,275 shares of the biopharmaceutical company’s stock worth $1,499,000 after acquiring an additional 14,032 shares in the last quarter. Finally, Keeley Teton Advisors LLC lifted its position in shares of Omeros by 32.3% during the first quarter. Keeley Teton Advisors LLC now owns 17,201 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 4,200 shares in the last quarter. Hedge funds and other institutional investors own 52.12% of the company’s stock.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: Oversold
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.